Gemphire Therapeutics

Gemphire Therapeutics is a clinical-stage biopharmaceutical company developing commercialized therapies to help patients with cardiometabolic disorders, including dyslipidemia and NASH. Its product CI-1027 provides a new therapeutic option for cardiometabolic diseases as an add-on to the standard of care, particularly benefiting patients on statins, as well as doctors and payers.